In this article, we provide a further update on developments regarding biosimilars in Canada (approvals, pending submissions, litigation, regulatory, market access and competition).
The Patented Medicine Prices Review Board (PMPRB) has released its 7th edition CompassRX report, Annual Public Drug Plan Expenditure Report for 2019/20. The report was prepared as part.
Share this article
Annual expenditures on drugs in public plans exceeded $12 billion in 2018-19
OTTAWA, ON, Dec. 18, 2020 /CNW/ - The latest edition of the Patented Medicine Prices Review Board s (PMPRB) CompassRx report reveals that prescription drug expenditures for the National Prescription Drug Utilization Information System (NPDUIS) public drug plans increased by 5.6% in 2018/19 to reach $12.1 billion, driven primarily by a considerable rise in the use of higher-cost drugs coupled with greater than average impacts from plan design changes and the use of generic drugs.
The PMPRB s
CompassRx report monitors and analyzes the cost pressures driving changes in prescription drug expenditures in Canadian public drug plans. This sixth edition of